Richard Francis Intended to be Appointed Purespring Therapeutics CEO Following Completion of Its Series A Financing of £45.0 Mil, from 1 February 2021

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

January 8, 2021

Richard Francis is a leading pharmaceutical executive with over 25 years’ experience in building sustainable, world-class life science companies. He most recently held the role of Chief Executive Officer of Sandoz, a division of Novartis. Sandoz is a global leader in generic pharmaceuticals and biosimilars. He was also a member of the Novartis Executive Committee.

Richard Francis joined Novartis from Biogen Idec, where he held global and country leadership positions during his 13-year career with the company. He has also worked at Sanofi-Synthelabo and Wyeth where he held various commercial roles.

In addition to his full-time role as Chief Executive of Purespring, Richard will spend part of his time as a Partner at SynconaInvestment Management Limited, providing valuable advice and bringing significant commercial and operational expertise across the Syncona portfolio.

Richard Francis, Chief Executive Officer of Purespring Therapeutics, said: I am delighted to be joining Purespring at the beginning of this exciting journey and to be building a world class gene therapy company. I was attracted to Purespring because of the strength of the science and the world-class founding team who are leading experts in the kidney and gene therapy fields.”

He added, “Purespring will be an agile, dynamic company that focuses on building a talented team that truly wants to make a difference to the millions of people suffering from kidney related diseases. I share Syncona’s passion for building sustainable life science companies that can deliver transformational medicines for patients and look forward to working with the team.”

Dominic Schmidt, Partner, Syncona Investment Management Limited, said: “At Syncona, we are thrilled to appoint a Chief Executive Officer of Richard’s calibre to operationalise Purespring and build out the organisation.”

“Richard Francis is an extremely accomplished executive with extensive and differentiated experience across the entire value chain. I look forward to working closely with him as we build Purespring into a global leader in renal gene therapy and his broad expertise will be valuable to Syncona as we seek to expand develop our portfolio.”

Purespring been founded around the seminal work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases. Purespring will seek to advance gene therapies for the treatment of chronic renal diseases that are currently poorly addressed with existing treatments.

Syncona’s £45.0 million commitment to Purespring will fund the company build-out and will enable it to progress to clinical stage. Syncona’s Chief Investment Officer, Chris Hollowood, has been appointed as Chairman and Syncona Partner Dominic Schmidt has joined the Board of Directors.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.